Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
ONCOSEC Investor Information Package IMMUNOPULSE aims to stimulate the body’s immune system in order to target and eliminate cancerous cells. If you’d like to discuss investment opportunities please contact us directly: Address — 9810 Summers Ridge Road Suite 110 San Diego CA 92121 Telephone — +1 855 662 6732 Email — [email protected] Website — www.OncoSec.com BENEFITS Administered in an outpatient setting. Electroporation increase uptake by up to 4000x Clinicians can combine with other therapeutic approaches Uses body’s own immune system to target and eliminate cancer May trigger a systemic response that reaches cancer cells beyond the treatment area WHERE DOES IMMUNOPULSE FIT? STAGE 1 STAGE II STAGE 111 A STAGE 111 B STAGE 111 C STAGE IV M1A STAGE IV M1B STAGE IV M1C SURGERY RADIATION YERVOY/ZELBORAF CHEMOTHERAPY IMMUNOPULSE Cancer cells surrounded by healthy cells. 4 During brief electroporation DNA-IL12 enters and starts to produce IL-12. 3 2 1 DNA IL-12 (a gene based immune trigger) is injected into tumor. Use electroporation to open microscopic pores in cell membrane, allowing the agent to enter. 6 5 IL-12 is produced, eliciting an immune response which enables the body to identify and kill cancerous cells. Cancerous cells now are detected as a result of the immune response. These cells are now a target to kill. 7 Studies to date have shown a systemic response (reduction in untreated tumors) METASTATIC MELANOMA STUDY | DNA IL-12 MOFFITT CANCER CENTRE — 24 Patients 1st human study using elctro-gene therapy 76% of lesions showed >20% reduction in size 53% of patients showed objective response* 16% of patients showed complete remission P HA S E I — ME L A NO MA DATA P HA S E I I — I N T E R I M ME L A NO MA DATA 61% of patients showed systemic response 48% of patients showed objective response* MULTI-CENTER 10% of patients showed complete remission — 21 Patients A total of 47 patients (Phase I & Phase II) have been treated to date without a single, drug-related serious adverse event. *includes stable disease ONCOSEC FINANCIALS Shares Outstanding Warrants Stock Options 183,494,299 67,749,301 6,659,500 EXCHANGE/SYMBOL: OTCQB : ONCS A N A LY S T C O V E R A G E NOBLE FINANCIAL MAXIM GROUP ONCOSEC IN THE MEDIA H.C. WAINRIGHT